Pfizer’s Exchange Offer and Tender Offer as Well as Tender Offer and Consent Solicitation


Simpson Thacher represented Morgan Stanley & Co. International plc, as dealer manager, in concurrent transactions by Pfizer Inc. in which Pfizer (i) offered to exchange any and all of its existing 6.5% Notes due 2038 held by eligible holders for newly issued 2.735% Notes due 2043 and, alternatively, offered to purchase for cash any and all of its outstanding 6.5% Notes due 2038, and (ii) offered to purchase for cash any and all of its outstanding 5.75% Notes due 2021 and solicited consents to amendments to the related indenture.

Pfizer is a research-based, global biopharmaceutical company. Pfizer’s global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products.

The Simpson Thacher team included John D. Lobrano (Picture), Joe Kaufman, Jonathan Ozner and Yoonji Woo (Capital Markets); Jacqueline Clinton and Brian Mendick (Tax); Marcela Robledo (Intellectual Property); Jamin Koslowe (Executive Compensation and Employee Benefits); Adeeb Fadil and Noreen Lavan (Environmental); and Jennie Getsin (FINRA and Blue Sky).

Involved fees earner: John Lobrano – Simpson Thacher & Bartlett; Joseph Kaufman – Simpson Thacher & Bartlett; Jonathan Ozner – Simpson Thacher & Bartlett; Yoonji Woo – Simpson Thacher & Bartlett; Jacqueline Clinton – Simpson Thacher & Bartlett; Brian Mendick – Simpson Thacher & Bartlett; Marcela Robledo – Simpson Thacher & Bartlett; Jamin Koslowe – Simpson Thacher & Bartlett; Adeeb Fadil – Simpson Thacher & Bartlett; Noreen Lavan – Simpson Thacher & Bartlett; Jennie Getsin – Simpson Thacher & Bartlett;

Law Firms: Simpson Thacher & Bartlett;

Clients: Morgan Stanley;

Avatar

Author: Ambrogio Visconti